MEDLINE Journals

    Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays.

    Authors

    Spanbauer AC, Casseday S, Davoudzadeh D, et al. 

    Institution

    IRP, NIDA, NIH, Baltimore, Maryland 21224, USA.

    Source

    J Anal Toxicol 2001 Oct; 25(7) :515-9.

    Abstract

    Heroin, with a plasma half-life of approximately 5 min, is rapidly metabolized to 6-acetylmorphine (6-AM). 6-AM, a specific marker for heroin use, which also has a short half-life of only 0.6 h, is detected in urine for only a few hours after heroin exposure. Ingestion of poppy seeds and/or licit opiate analgesics can produce positive urine opiate tests. This has complicated the interpretation of positive opiate results and contributed to the decision to raise opiate cutoff concentrations and to require 6-AM confirmation in federally mandated workplace drug-testing programs. Microgenics Corp. has developed the CEDIA 6-AM assay, a homogeneous enzyme immunoassay for semiquantitative determination of 6-AM in human urine, in addition to its CEDIA DAU opiate assay. Urine specimens were collected 3 times per week from 27 participants enrolled in a clinical research trial evaluating a contingency management treatment program for heroin and cocaine abuse. Of the 1377 urine specimens screened, 261 (18.9%) were positive for opiates at > or = 300 ng/mL, 153 (11.1%) were positive for opiates at > or = 2000 ng/mL, and 55 (4.0%) were positive for 6-AM at > or = 10 ng/mL. For opiate-positive screens > or = 300 and > or = 2000 ng/mL, 91.3% and 80.8% confirmed positive for morphine or codeine at the respective gas chromatography-mass spectrometry (GC-MS) cutoffs. All specimens screening positive for 6-AM also confirmed positive by GC-MS at > or = 10 ng/mL. Increasing the opiate screening and confirmation cutoffs for the federal workplace drug-testing program resulted in 8% fewer opiate-positive tests; however, recent heroin use was not affected by this change.

    Mesh

    Adolescent
    Adult
    Cocaine-Related Disorders
    Codeine
    False Positive Reactions
    Female
    Gas Chromatography-Mass Spectrometry
    Heroin Dependence
    Humans
    Immunoenzyme Techniques
    Male
    Methadone
    Middle Aged
    Morphine
    Morphine Derivatives
    Narcotics
    Sensitivity and Specificity
    Substance Abuse Detection
    Workplace

    Language

    eng

    Pub Type(s)

    Evaluation Studies Journal Article

    PubMed ID

    11599593

    Content Manager
    Related Content

    Comparison of the Microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for the detection of heroin use in forensic urine samples.

    Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing.

    Detection times and analytical performance of commercial urine opiate immunoassays following heroin administration.

    Paradoxical results in urine drug testing for 6-acetylmorphine and total opiates: implications for best analytical strategy.

    Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine.

    Experience with a urine opiate screening and confirmation cutoff of 2000 ng/mL.

    Concentrations of unconjugated morphine, codeine and 6-acetylmorphine in urine specimens from suspected drugged drivers.

    Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times.